WASHINGTON (Reuters) – Global drugmakers could face new U.S. scrutiny after a report from lawmakers in India alleged abuses in that country’s drug approval process, lawyers familiar with such investigations said.
WASHINGTON (Reuters) – Global drugmakers could face new U.S. scrutiny after a report from lawmakers in India alleged abuses in that country’s drug approval process, lawyers familiar with such investigations said.
